Liquid Biopsy that Looks Deeper

Our proprietary Plasma-Sieve apheresis device and methods leverage a high-affinity adsorption matrix to selectively capture and purify circulating cell-free DNA (cfDNA) directly from plasma with yields in micrograms, not nanograms.

Microgram-scale yields of cfDNA enable us to construct Ultra-Deep cfDNA Libraries for next-gen sequencing panels in MCED testing while also interrogating vastly larger cfDNA inputs by digital PCR in tumor-informed MRD assays, improving the analytical limits of detection (LOD) for cfDNA tumor markers by 100- to 1000-fold.

A new frontier of sensitivity in assays for minimal/microscopic residual disease (MRD) and in multi-cancer early detection (MCED) tests, where every cfDNA fragment is critical.

By sampling the entire circulating cfDNA pool, we overcome the stochastic sampling limits of 10 mL blood draws, enabling high-confidence MCED screening even for cancers with ultra-low variant allele frequencies (VAF).